Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Neuropsychiatric symptoms in early and late onset Alzheimer’s Disease
Aging, Dementia, and Behavioral Neurology
Aging and Dementia Posters (7:00 AM-5:00 PM)
081
To determine the differential trajectories of the NPS in EOAD and LOAD, in a cohort of amyloid positive patients.
The faster rates of cognitive decline and the predominance of atypical forms in early onset Alzheimer’s Disease (EOAD) suggests that neuropsychiatric symptoms (NPS) could be more common in EOAD than in late-onset AD (LOAD). However, prior studies based in non-biomarker diagnosed cohorts show discordant results. 

115 participants meeting NIA-AA criteria for AD, using amyloid-PET, were recruited at Memory and Aging Center, UCSF. Participants were classified as EOAD (age of onset ≤ 65 years; n=69) or LOAD (> 65 years; n=46). The caregiver-reported Neuropsychiatric Inventory – Questionnaire (NPI-Q) was assessed at baseline and follow-up (annual visits, from 1 to 8 years). NPI-Q mean comparisons at baseline and regression models adjusted by Clinical Dementia Rating (CDR) longitudinally, were performed to determine the effect of EOAD/LOAD diagnosis in NPI-Q scores. The interaction with amnestic/non-amnestic variants was also evaluated.
There were no differences between EOAD and LOAD for gender (51 vs 59%), global cognition (MMSE 23.4±5 vs 24.7±5) or functional performance (CDR Total 0.6±0.2 vs 0.6±0.3). Both groups were primarily amnestic AD (EOAD 71%, LOAD 80%). At baseline, both the NPI Total scores and certain subdomains scores (anxiety, irritability and nighttime behaviors) were higher in EOAD compared to LOAD (p<0.05). Longitudinally, EOAD predicted higher scores in NPI Total (p<0.01), nighttime behavior and motor disturbances (p<0.05). Non-amnestic EOAD showed higher anxiety than amnestic EOAD (p<0.05). 
NPS are more severe in EOAD than LOAD along the disease course, independent of the disease stage (CDR). Certain domains such as anxiety, irritability, nighttime behaviors and motor disturbances contribute to the differential pattern of NPS, suggesting there is a need to develop more tailored treatment strategies to address these clinical manifestations in EOAD.
Authors/Disclosures
Neus Falgàs Martínez (UCSF)
PRESENTER 		Neus Falgàs Martínez has nothing to disclose.
Neus Falgàs Martínez (UCSF) Neus Falgàs Martínez has nothing to disclose.
Joel Kramer, PhD (UCSF Medical Center) The institution of Dr. Kramer has received research support from tau consortium. Dr. Kramer has received publishing royalties from a publication relating to health care.
Howard J. Rosen, MD (UCSF) Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Bruce L. Miller, MD, FÂ鶹´«Ã½Ó³»­ (University of California, San Francisco) Dr. Miller has nothing to disclose.
Gil D. Rabinovici, MD, FÂ鶹´«Ã½Ó³»­ (UCSF Memory & Aging Center) Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alector. Dr. Rabinovici has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Norodisk. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Consultant for C2N. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Joihnson. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Peerview. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Rabinovici has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA. The institution of Dr. Rabinovici has received research support from NIH. The institution of Dr. Rabinovici has received research support from American College of Radiology. The institution of Dr. Rabinovici has received research support from Alzheimer's Association. The institution of Dr. Rabinovici has received research support from Rainwater Charitable Foundation. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Topic Chair, Course Director and teacher with Â鶹´«Ã½Ó³»­. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Grant reviewer with NIH. Dr. Rabinovici has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with ANA.
Lea Grinberg Lea Grinberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Curasen Inc. The institution of Lea Grinberg has received research support from NIH. The institution of Lea Grinberg has received research support from Eli Lilly. The institution of Lea Grinberg has received research support from BrightFouus. The institution of Lea Grinberg has received research support from Rainwater Charity Foundation.
Thomas Neylan (University of California, San Francisco) The institution of Thomas Neylan has received research support from National Institutes of Aging.
Christine M. Walsh, PhD (UCSF) Dr. Walsh has nothing to disclose.